Tag: chronic lower back pain market forecast

Uncover key drivers, emerging technologies, and competitive movements shaping the chronic lower back pain market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Chronic Lower Back Pain Market in 2030?

The chronic lower back pain market size has experienced consistent expansion in recent years. It is projected to grow from $8.04 billion in 2025 to $8.41 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 4.6%. The historical growth of this market can be attributed to an increasing aging population, rising prevalence of musculoskeletal disorders, growing sedentary lifestyles, a higher incidence of workplace-related back injuries, and expanded access to diagnostic imaging.

The chronic lower back pain market is anticipated to exhibit sustained expansion over the coming years, with its value projected to reach $10.06 billion by 2030, advancing at a compound annual growth rate (CAGR) of 4.6%. This growth during the forecast period is fueled by factors such as an escalating demand for non-invasive interventions, the increasing embrace of digital therapeutics, the broadening scope of outpatient pain management offerings, a greater emphasis on personalized medicine, and augmented investments in chronic pain research. Noteworthy trends for this period include a wider adoption of multimodal pain management strategies, an increased utilization of minimally invasive procedures, the growing integration of digital instruments for pain monitoring, an expansion of tailored treatment approaches, and a heightened focus on non-opioid pain therapies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9946&type=smp

What Drivers Are Influencing Production Trends In The Chronic Lower Back Pain Market?

The chronic lower back pain market is projected to see growth, influenced significantly by the expanding geriatric population. This group comprises individuals aged 65 years and above. Within this demographic, age-related neurodegenerative and musculoskeletal conditions, such as arthritis and osteoarthritis, accelerate, causing weakness and painful complaints that culminate in chronic back pain and diminished physical activity. To illustrate, in May 2024, the Administration for Community Living, a US-based government agency, revealed that in 2022, 17.3% of the populace had reached 65 years or more. This proportion is forecast to reach 22% by 2040. Consequently, the rising geriatric population is acting as a primary catalyst for the chronic lower back pain market’s expansion.

Which Segments Are Gaining Traction In The Chronic Lower Back Pain Market?

The chronic lower back pain market covered in this report is segmented –

1) By Type Of Pain: Diskogenic Pain, Lumbar Spinal Stenosis, Sacroiliac Pain, Facet-Joint Pain, Radicular Pain, Muscular Pain, Other Types Of Pain

2) By Diagnosis: Clinical History, Physical Examination, Imaging Guidelines, Assessment Of Pain

3) By End-User: Hospitals, Orthopedic Clinics, Ambulatory Surgery Centers, Other End-Users

Subsegments:

1) By Diskogenic Pain: Herniated Disc, Degenerative Disc Disease, Disc Bulge, Lumbar Spinal Stenosis

2) By Lumbar Spinal Stenosis: Central Stenosis, Lateral Stenosis

3) By Sacroiliac Pain: Sacroiliac Joint Dysfunction, Inflammatory Conditions

4) By Facet-Joint Pain: Facet Joint Syndrome, Osteoarthritis Of The Facet Joints

5) By Radicular Pain: Sciatica, Nerve Root Compression

6) By Muscular Pain: Muscle Strain, Muscle Spasm

7) By Other Types Of Pain: Myofascial Pain Syndrome, Spondylolisthesis, Osteoporosis-Related Pain

What Trends Are Projected To Support The Growth Of The Chronic Lower Back Pain Market?

Leading firms within the chronic lower back pain market are creating offerings that incorporate sophisticated technologies, such as BurstDR SCS technology, to provide patients with novel therapeutic choices. This BurstDR SCS technology represents a unique spinal cord stimulation (SCS) treatment modality, functioning by employing gentle electrical impulses to modify pain signals on their journey from the spinal cord to the brain. An illustrative example is Abbott Laboratories, a medical device company based in the US, which secured FDA approval in May 2023 for its Spinal Cord Stimulation (SCS) devices, specifically the Proclaim SCS Family and Eterna SCS System, intended for managing chronic back pain. These SCS devices from Abbott utilize their patented BurstDR stimulation waveform, an enhanced therapeutic approach crafted to more accurately replicate the transmission of pain signals to the brain and address the emotional distress associated with pain, a departure from conventional tonic stimulation.

Who Are The Primary Competitors In The Global Chronic Lower Back Pain Market?

Major companies operating in the chronic lower back pain market are Pfizer Inc., Johnson & Johnson Private Limited, Sanofi S.A., Endo Pharmaceuticals plc, Merck Corporation, Vertebral Technologies Inc., Medtronic plc, Boston Scientific Corporation, BioWave Corporation, Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., SpineThera Inc., Dr. Reddy’s Laboratories Ltd., Celgene Corporation, Axsome Therapeutics Inc., Mesoblast Limited, Frontier Biotechnologies Inc., Eli Lilly and Company, Persica Pharmaceuticals, Abbott Laboratories, Hisamitsu Pharmaceutical Co. Inc., Ipsen S.A., Daiichi Sankyo Company Ltd., Zimmer Biomet Holdings Inc., Novartis International AG, Janssen Pharmaceuticals Inc., Insys Therapeutics Inc., Collegium Pharmaceutical Inc., Cara Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/chronic-lower-back-pain-global-market-report

Which Regions Are Projected To Dominate The Chronic Lower Back Pain Market In The Coming Years?

North America was the largest region in the chronic lower back pain market in 2025. The regions covered in the chronic lower back pain market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Chronic Lower Back Pain Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=9946&type=smp

Browse Through More Reports Similar to the Global Chronic Lower Back Pain Market 2026, By The Business Research Company

Muscle Pain Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/muscle-pain-treatment-global-market-report

Chronic Pain Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-pain-global-market-report

Neuropathic Pain Market Report 2026

https://www.thebusinessresearchcompany.com/report/neuropathic-pain-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What CAGR And Valuation Are Anticipated For The Chronic Lower Back Pain Market?

The market size of chronic lower back pain has experienced consistent escalation in the past few years. Expecting to surge from $7.72 billion in 2024 to $8.04 billion in 2025, the market’s compound annual growth rate (CAGR) stands at around 4.1%. The growth during the historic period can be ascribed to idle lifestyles, physical work, professional hazards, advancements in medical diagnosis, evolving pain management techniques, and epidemiological research.

The market for chronic lower back pain is projected to witness consistent expansion in the ensuing years, achieving a value of $9.63 billion by 2029 with a compound annual growth rate (CAGR) of 4.6%. This predicted surge during the forecast timeframe can be credited to a number of factors such as increased non-pharmacological interventions, advance in preventive healthcare measures, emphasis on comprehensive treatments, the advent of regenerative medicine, and aging demographics. The forecast period is also expected to highlight predominant trends such as a greater focus on non-pharmacological interventions, a shift in pain management strategies, enhanced healthcare cognizance and education, use of telemedicine and remote monitoring, and inclusion of regenerative medicine.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9946&type=smp

What Are The Primary Factors Supporting The Chronic Lower Back Pain Market Expansion?

The chronic lower back pain market is predicted to expand due to an expected rise in the occurrence of nerve instances. Nerve instances are specific instances where an individual shows courage, bravery, or persistence when faced with difficult or intimidating circumstances. Persistent exposure to stress and pain can lead to a phenomenon known as central sensitization, where the nervous system becomes extremely sensitive, experiencing pain more intensely even if there’s no actual injury. For example, in July 2023, as reported by Nature, a UK scientific journal that is published weekly, the rate of peripheral neuropathy, which correlates to nerve damage, stood at 28.4% in adults aged 40 or over with diabetes and 11.8% in those without diabetes. Thus, the rise in the frequency of nerve instances is a major factor propelling the growth of the chronic lower back pain market.

Which Segments Define The Structure Of The Chronic Lower Back Pain Market?

The chronic lower back painmarket covered in this report is segmented –

1) By Type Of Pain: Diskogenic Pain; Lumbar Spinal Stenosis; Sacroiliac Pain; Facet-Joint Pain; Radicular Pain; Muscular Pain; Other Types Of Pain

2) By Diagnosis: Clinical History; Physical Examination; Imaging Guidelines; Assessment Of Pain

3) By End-User: Hospitals; Orthopedic Clinics; Ambulatory Surgery Centers; Other End-Users

Subsegments:

1) By Diskogenic Pain: Herniated Disc; Degenerative Disc Disease; Disc Bulge; Lumbar Spinal Stenosis

2) By Lumbar Spinal Stenosis: Central Stenosis; Lateral Stenosis

3) By Sacroiliac Pain: Sacroiliac Joint Dysfunction; Inflammatory Conditions

4) By Facet-Joint Pain: Facet Joint Syndrome; Osteoarthritis Of The Facet Joints

5) By Radicular Pain: Sciatica; Nerve Root Compression

6) By Muscular Pain: Muscle Strain; Muscle Spasm

7) By Other Types of Pain: Myofascial Pain Syndrome; Spondylolisthesis; Osteoporosis-Related Pain

Which Long-Term Trends Will Play A Crucial Role In The Chronic Lower Back Pain Market?

Significant players in the chronic lower back pain market are prioritizing the creation of groundbreaking pharmaceuticals to serve their clientele and maintain their market standing. The invention of novel drugs can enhance treatment results for people suffering from various ailments. For instance, Amneal Pharmaceuticals, an American pharmaceutical corporation, unveiled LYVISPAH, a FDA-approved baclofen oral granule (5, 10, and 20 mg), in July 2022. The drug is designed to tackle spasticity associated with multiple sclerosis and other spinal cord disorders. LYVISPAH is effective in managing and alleviating flexor spasms and related pain, clones, and muscular rigidity. The medication offers a customizable dosage with single-dose granule packets available in doses of 5 mg, 10 mg, and 20 mg and is equivalent to oral baclofen tablets. LYVISPAH could significantly improve the quality of life for patients suffering from spinal cord injuries and other related diseases.

Who Are The Primary Market Leaders In The Chronic Lower Back Pain Market?

Major companies operating in the chronic lower back pain market include Pfizer Inc., Johnson & Johnson Private Limited, Sanofi S.A., Endo Pharmaceuticals plc, Merck Corporation, Vertebral Technologies Inc., Medtronic plc, Boston Scientific Corporation, BioWave Corporation, Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., SpineThera Inc., Dr. Reddy’s Laboratories Ltd., Celgene Corporation, Axsome Therapeutics Inc., Mesoblast Limited, Frontier Biotechnologies Inc., Eli Lilly and Company, Persica Pharmaceuticals, Abbott Laboratories, Hisamitsu Pharmaceutical Co. Inc., Ipsen S.A., Daiichi Sankyo Company Ltd., Zimmer Biomet Holdings Inc., Novartis International AG, Janssen Pharmaceuticals Inc., Insys Therapeutics Inc., Collegium Pharmaceutical Inc., Cara Therapeutics Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/chronic-lower-back-pain-global-market-report

What Regional Factors Are Accelerating Growth In The Chronic Lower Back Pain Market?

North America was the largest region in the chronic lower back pain market in 2024. The regions covered in the chronic lower back pain market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=9946&type=smp

Browse Through More Reports Similar to the Global Chronic Lower Back Pain Market 2025, By The Business Research Company

Iot In Manufacturing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/iot-in-manufacturing-global-market-report

Power Generators Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/power-generators-global-market-report

Ventricular Assist Device Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/ventricular-assist-device-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

By How Much Is The Chronic Lower Back Pain Market Expected To Expand Between 2025 And 2029?

The market size for chronic lower back pain has shown consistent expansion over recent years. It is anticipated to expand from $7.72 billion in 2024 to $8.04 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 4.1%. This historical growth can be attributed to influences like sedentary lifestyles, manual labor and occupational risks, advancements in medical diagnosis, the progression of pain management techniques, and insights from epidemiological studies.

The market size for chronic lower back pain is projected to experience consistent expansion over the upcoming years. This market is predicted to reach “$9.63 billion in 2029, demonstrating a compound annual growth rate (CAGR) of 4.6%. Factors contributing to this growth during the forecast period include an increase in non-pharmacological interventions, various preventive healthcare initiatives, a heightened focus on holistic treatments, advancements in regenerative medicine development, and the ongoing aging population trends. Key trends anticipated during the forecast period involve a greater emphasis on non-pharmacological interventions, a notable shift in pain management approaches, enhanced healthcare awareness and education, the expansion of telemedicine and remote monitoring, and the increasing integration of regenerative medicine.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9946&type=smp

What Are The Drivers Pushing New Developments In The Chronic Lower Back Pain Market?

An uptick in the occurrence of nerve instances is anticipated to fuel the expansion of the chronic lower back pain market. Nerve instances refer to particular events or scenarios where an individual exhibits bravery, courage, or resilience when facing a challenging or daunting situation. Sustained exposure to stress and discomfort can result in a phenomenon known as central sensitization. This fundamentally signifies that the nervous system becomes excessively sensitive, experiencing pain with greater intensity, even when no actual injury is present. For instance, in July 2023, as per Nature, a UK-based weekly scientific journal, the prevalence of peripheral neuropathy, which is associated with nerve damage, is reported to be 28.4% in adults aged 40 or older with diabetes and 11.8% in those without diabetes. Consequently, a rise in the frequency of nerve instances is propelling the growth of the chronic lower back pain market.

What Are The Leading Segments Analyzed In The Chronic Lower Back Pain Market?

The chronic lower back painmarket covered in this report is segmented –

1) By Type Of Pain: Diskogenic Pain; Lumbar Spinal Stenosis; Sacroiliac Pain; Facet-Joint Pain; Radicular Pain; Muscular Pain; Other Types Of Pain

2) By Diagnosis: Clinical History; Physical Examination; Imaging Guidelines; Assessment Of Pain

3) By End-User: Hospitals; Orthopedic Clinics; Ambulatory Surgery Centers; Other End-Users

Subsegments:

1) By Diskogenic Pain: Herniated Disc; Degenerative Disc Disease; Disc Bulge; Lumbar Spinal Stenosis

2) By Lumbar Spinal Stenosis: Central Stenosis; Lateral Stenosis

3) By Sacroiliac Pain: Sacroiliac Joint Dysfunction; Inflammatory Conditions

4) By Facet-Joint Pain: Facet Joint Syndrome; Osteoarthritis Of The Facet Joints

5) By Radicular Pain: Sciatica; Nerve Root Compression

6) By Muscular Pain: Muscle Strain; Muscle Spasm

7) By Other Types of Pain: Myofascial Pain Syndrome; Spondylolisthesis; Osteoporosis-Related Pain

What Trends Are Redefining The Chronic Lower Back Pain Market Dynamics?

Companies operating within the chronic lower back pain market are concentrating on creating novel medications to serve their clients and maintain their competitive standing. The creation of advanced pharmaceuticals has the potential to enhance therapeutic results for individuals suffering from diverse conditions. As an example, in July 2022, Amneal Pharmaceuticals, a US-based pharmaceutical firm, introduced LYVISPAH, an oral granule formulation of baclofen (5, 10, and 20 mg), which received approval from the U.S. Food and Drug Administration (FDA) for managing spasticity linked to multiple sclerosis and other conditions affecting the spinal cord. LYVISPAH addresses and alleviates flexor spasms, along with their accompanying pain, clonus, and muscle stiffness. This medication offers adaptable, customized dosing through individual granule packets available in 5 mg, 10 mg, and 20 mg strengths, and it demonstrates bioequivalence to existing oral baclofen tablets. Individuals experiencing spinal cord injuries and other spinal cord-related ailments could also derive advantages from the use of LYVISPAH.

Which Major Firms Are Strengthening Their Position In The Chronic Lower Back Pain Industry?

Major companies operating in the chronic lower back pain market include Pfizer Inc., Johnson & Johnson Private Limited, Sanofi S.A., Endo Pharmaceuticals plc, Merck Corporation, Vertebral Technologies Inc., Medtronic plc, Boston Scientific Corporation, BioWave Corporation, Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., SpineThera Inc., Dr. Reddy’s Laboratories Ltd., Celgene Corporation, Axsome Therapeutics Inc., Mesoblast Limited, Frontier Biotechnologies Inc., Eli Lilly and Company, Persica Pharmaceuticals, Abbott Laboratories, Hisamitsu Pharmaceutical Co. Inc., Ipsen S.A., Daiichi Sankyo Company Ltd., Zimmer Biomet Holdings Inc., Novartis International AG, Janssen Pharmaceuticals Inc., Insys Therapeutics Inc., Collegium Pharmaceutical Inc., Cara Therapeutics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/chronic-lower-back-pain-global-market-report

What Regional Growth Trends Are Shaping The Chronic Lower Back Pain Market Outlook?

North America was the largest region in the chronic lower back pain market in 2024. The regions covered in the chronic lower back pain market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Chronic Lower Back Pain Market Report:

https://www.thebusinessresearchcompany.com/customise?id=9946&type=smp

Browse Through More Reports Similar to the Global Chronic Lower Back Pain Market 2025, By The Business Research Company

Iot In Manufacturing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/iot-in-manufacturing-global-market-report

Power Generators Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/power-generators-global-market-report

Ventricular Assist Device Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/ventricular-assist-device-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What is the Projected CAGR for the Chronic Lower Back Pain Market Size from 2025 to 2034?#_x000D_

The market size for chronic lower back pain has seen consistent growth in recent years. There’s an anticipated growth from $7.72 billion in 2024 to reach $8.04 billion by 2025, yielding a compound annual growth rate (CAGR) of 4.1%. The significant growth observed over the historical period can be credited to factors such as sedentary living conditions, risks associated with manual labor and occupations, advancements in medical diagnosis, evolution in pain management, and epidemiological research._x000D_

_x000D_

The market size for chronic lower back pain is predicted to experience consistent growth in the imminent years, culminating in a value of $9.63 billion by 2029, achieving a compound annual growth rate (CAGR) of 4.6%. The increased growth during the forecast period can be ascribed to the upsurge in non-pharmacological treatments, the rise of preventive healthcare measures, emphasis on comprehensive therapies, advancement in regenerative medicine, and an aging populace. Main trends for the anticipated period include greater concentration on non-pharmacological treatments, transformation in pain management strategies, enhanced healthcare consciousness and tutoring, telehealth and remote patient monitoring, and incorporation of regenerative medicine._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=9946&type=smp_x000D_

_x000D_

#What Are the Major Market Drivers Behind the Rising Adoption of Chronic Lower Back Pain Market?#_x000D_

The escalation in the occurrence of nerve-related instances is anticipated to fuel the expansion of the chronic lower back pain market. These instances concern specific events or situations where an individual showcases bravery, courage, or resilience amid challenging or intimidating conditions. Repeated exposure to stress and pain can lead to a condition known as central sensitization, whereby the nervous system becomes extremely sensitive, experiencing pain more severely, even without a real injury. For example, in July 2023, Nature, a UK-based weekly science journal, reported that the prevalence of peripheral neuropathy, related to nerve damage, was noted to be 28.4% in adults aged 40 or older with diabetes, and 11.8% in those devoid of diabetes. Consequently, the rise in the occurrence of nerve-related instances is propelling the development of the chronic lower back pain market._x000D_

_x000D_

#Which Key Market Segments Comprise the Chronic Lower Back Pain Market and Drive Its Revenue Growth?#_x000D_

The chronic lower back painmarket covered in this report is segmented – _x000D_

_x000D_

1) By Type Of Pain: Diskogenic Pain; Lumbar Spinal Stenosis; Sacroiliac Pain; Facet-Joint Pain; Radicular Pain; Muscular Pain; Other Types Of Pain_x000D_

2) By Diagnosis: Clinical History; Physical Examination; Imaging Guidelines; Assessment Of Pain_x000D_

3) By End-User: Hospitals; Orthopedic Clinics; Ambulatory Surgery Centers; Other End-Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Diskogenic Pain: Herniated Disc; Degenerative Disc Disease; Disc Bulge; Lumbar Spinal Stenosis _x000D_

2) By Lumbar Spinal Stenosis: Central Stenosis; Lateral Stenosis _x000D_

3) By Sacroiliac Pain: Sacroiliac Joint Dysfunction; Inflammatory Conditions _x000D_

4) By Facet-Joint Pain: Facet Joint Syndrome; Osteoarthritis Of The Facet Joints _x000D_

5) By Radicular Pain: Sciatica; Nerve Root Compression _x000D_

6) By Muscular Pain: Muscle Strain; Muscle Spasm _x000D_

7) By Other Types of Pain: Myofascial Pain Syndrome; Spondylolisthesis; Osteoporosis-Related Pain _x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=9946&type=smp_x000D_

_x000D_

#Which Areas Are Leading Regions in the Chronic Lower Back Pain Market Expansion Across the Globe?#_x000D_

North America was the largest region in the chronic lower back pain market in 2024. The regions covered in the chronic lower back pain market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

_x000D_

#What Key Trends Are Shaping the Future of the Chronic Lower Back Pain Market?#_x000D_

Leading companies in the chronic lower back pain market are concentrating on the advancement of novel medications to cater to their clients and maintain their standing in the industry. The invention of new drugs has the potential to enhance therapeutic results for people suffering from various conditions. For instance, Amneal Pharmaceuticals, an American pharmaceutical firm, introduced LYVISPAH in July 2022. This baclofen oral granule, approved by the FDA in dosages of 5, 10, and 20 mg, is effective in treating spasticity related to multiple sclerosis and other spinal cord disorders. LYVISPAH targets and alleviates flexor spasms and related pain, clones, and muscular rigidity. It features a flexible, customised dosage in single-dose packages of 5 mg, 10 mg, and 20 mg, mirroring the bioequivalence of oral baclofen tablets. Those suffering from spinal cord injuries and other spinal cord disorders might find LYVISPAH beneficial._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/chronic-lower-back-pain-global-market-report_x000D_

_x000D_

#How Is the Chronic Lower Back Pain Market Conceptually Defined?#_x000D_

Chronic low back pain (CLBP) refers to a pain that persists for 12 weeks or more despite the treatment of the underlying cause of acute low back pain or the initial injury. Chronic low back pain is the major cause of disability and psychological issues such as stress, depression, and/or anxiety._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9946_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What is the Projected CAGR for the Chronic Lower Back Pain Market Size from 2025 to 2034?

The market size for chronic lower back pain has seen consistent growth in recent years. There’s an anticipated growth from $7.72 billion in 2024 to reach $8.04 billion by 2025, yielding a compound annual growth rate (CAGR) of 4.1%. The significant growth observed over the historical period can be credited to factors such as sedentary living conditions, risks associated with manual labor and occupations, advancements in medical diagnosis, evolution in pain management, and epidemiological research.

The market size for chronic lower back pain is predicted to experience consistent growth in the imminent years, culminating in a value of $9.63 billion by 2029, achieving a compound annual growth rate (CAGR) of 4.6%. The increased growth during the forecast period can be ascribed to the upsurge in non-pharmacological treatments, the rise of preventive healthcare measures, emphasis on comprehensive therapies, advancement in regenerative medicine, and an aging populace. Main trends for the anticipated period include greater concentration on non-pharmacological treatments, transformation in pain management strategies, enhanced healthcare consciousness and tutoring, telehealth and remote patient monitoring, and incorporation of regenerative medicine.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9946&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of Chronic Lower Back Pain Market?

The escalation in the occurrence of nerve-related instances is anticipated to fuel the expansion of the chronic lower back pain market. These instances concern specific events or situations where an individual showcases bravery, courage, or resilience amid challenging or intimidating conditions. Repeated exposure to stress and pain can lead to a condition known as central sensitization, whereby the nervous system becomes extremely sensitive, experiencing pain more severely, even without a real injury. For example, in July 2023, Nature, a UK-based weekly science journal, reported that the prevalence of peripheral neuropathy, related to nerve damage, was noted to be 28.4% in adults aged 40 or older with diabetes, and 11.8% in those devoid of diabetes. Consequently, the rise in the occurrence of nerve-related instances is propelling the development of the chronic lower back pain market.

Which Key Market Segments Comprise the Chronic Lower Back Pain Market and Drive Its Revenue Growth?

The chronic lower back painmarket covered in this report is segmented –

1) By Type Of Pain: Diskogenic Pain; Lumbar Spinal Stenosis; Sacroiliac Pain; Facet-Joint Pain; Radicular Pain; Muscular Pain; Other Types Of Pain

2) By Diagnosis: Clinical History; Physical Examination; Imaging Guidelines; Assessment Of Pain

3) By End-User: Hospitals; Orthopedic Clinics; Ambulatory Surgery Centers; Other End-Users

Subsegments:

1) By Diskogenic Pain: Herniated Disc; Degenerative Disc Disease; Disc Bulge; Lumbar Spinal Stenosis

2) By Lumbar Spinal Stenosis: Central Stenosis; Lateral Stenosis

3) By Sacroiliac Pain: Sacroiliac Joint Dysfunction; Inflammatory Conditions

4) By Facet-Joint Pain: Facet Joint Syndrome; Osteoarthritis Of The Facet Joints

5) By Radicular Pain: Sciatica; Nerve Root Compression

6) By Muscular Pain: Muscle Strain; Muscle Spasm

7) By Other Types of Pain: Myofascial Pain Syndrome; Spondylolisthesis; Osteoporosis-Related Pain

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=9946&type=smp

Which Areas Are Leading Regions in the Chronic Lower Back Pain Market Expansion Across the Globe?

North America was the largest region in the chronic lower back pain market in 2024. The regions covered in the chronic lower back pain market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Key Trends Are Shaping the Future of the Chronic Lower Back Pain Market?

Leading companies in the chronic lower back pain market are concentrating on the advancement of novel medications to cater to their clients and maintain their standing in the industry. The invention of new drugs has the potential to enhance therapeutic results for people suffering from various conditions. For instance, Amneal Pharmaceuticals, an American pharmaceutical firm, introduced LYVISPAH in July 2022. This baclofen oral granule, approved by the FDA in dosages of 5, 10, and 20 mg, is effective in treating spasticity related to multiple sclerosis and other spinal cord disorders. LYVISPAH targets and alleviates flexor spasms and related pain, clones, and muscular rigidity. It features a flexible, customised dosage in single-dose packages of 5 mg, 10 mg, and 20 mg, mirroring the bioequivalence of oral baclofen tablets. Those suffering from spinal cord injuries and other spinal cord disorders might find LYVISPAH beneficial.

View the full report here:

https://www.thebusinessresearchcompany.com/report/chronic-lower-back-pain-global-market-report

How Is the Chronic Lower Back Pain Market Conceptually Defined?

Chronic low back pain (CLBP) refers to a pain that persists for 12 weeks or more despite the treatment of the underlying cause of acute low back pain or the initial injury. Chronic low back pain is the major cause of disability and psychological issues such as stress, depression, and/or anxiety.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9946

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Chronic Lower Back Pain Market Grown from 2024 to 2025?

The market size for chronic lower back pain has been consistently expanding over the past few years. Projections forecast an increase from $7.72 billion in 2024 to approximately $8.08 billion in 2025, with a compound annual growth rate (CAGR) of 4.6%. Factors contributing to growth during the historic period include the rise of sedentary lifestyles, risks associated with manual labor and certain occupations, advancements in medical diagnosis, evolution in pain management techniques, and significant epidemiological research.

What Growth Rate Is Anticipated for the Chronic Lower Back Pain Market in the Coming Years?

The market size of chronic lower back pain is anticipated to significantly increase over the next few years, with a projection to reach $9.99 billion in 2029 and a compound annual growth rate (CAGR) of 5.5%. This escalation during the forecast period could be associated with the increase in non-pharmacological interventions, preventive healthcare actions, the emphasis on comprehensive treatments, advancement in regenerative medicine, and aging population patterns. Key trends during the outlook period involve attention on non-pharmacological interventions, changes in pain management techniques, awareness and education in healthcare, telemedicine along with remote surveillance, and the assimilation of regenerative medicine.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9946&type=smp

Who Are the Leading Companies in the Chronic Lower Back Pain Market?

Major companies operating in the chronic lower back pain market include Pfizer Inc., Johnson & Johnson Private Limited, Sanofi S.A., Endo Pharmaceuticals plc, Merck Corporation, Vertebral Technologies Inc., Medtronic plc, Boston Scientific Corporation, BioWave Corporation, Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., SpineThera Inc., Dr. Reddy’s Laboratories Ltd., Celgene Corporation, Axsome Therapeutics Inc., Mesoblast Limited, Frontier Biotechnologies Inc., Eli Lilly and Company, Persica Pharmaceuticals, Abbott Laboratories, Hisamitsu Pharmaceutical Co. Inc., Ipsen S.A., Daiichi Sankyo Company Ltd., Zimmer Biomet Holdings Inc., Novartis International AG, Janssen Pharmaceuticals Inc., Insys Therapeutics Inc., Collegium Pharmaceutical Inc., Cara Therapeutics Inc.

What Are the Key Drivers of the Chronic Lower Back Pain Market?

The chronic lower back pain market is predicted to expand as a result of a rise in the number of nerve instances. These instances are described as specific events or situations where an individual demonstrates bravery, courage, or resilience when confronted with a demanding or intimidating scenario. Prolonged exposure to stress and pain may result in a phenomenon known as central sensitization, effectively making the nervous system hyper-reactive and intensifying the perception of pain even in the absence of a physical injury. For example, a UK-based weekly scientific journal, Nature, reported in July 2023 that the prevalence of peripheral neuropathy associated with nerve damage was 28.4% in adults aged 40 or older with diabetes and 11.8% in those without diabetes. Consequently, the increase in nerve instances is stimulating the expansion of the chronic lower back pain market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9946&type=smp

What Are the Key Market Segments in the Chronic Lower Back Pain Industry?

The chronic lower back pain market covered in this report is segmented –

1) By Type Of Pain: Diskogenic Pain, Lumbar Spinal Stenosis, Sacroiliac Pain, Facet-Joint Pain, Radicular Pain, Muscular Pain, Other Types Of Pain

2) By Diagnosis: Clinical History, Physical Examination, Imaging Guidelines, Assessment Of Pain

3) By End-User: Hospitals, Orthopedic Clinics, Ambulatory Surgery Centers, Other End-Users

Subsegments:

1) By Diskogenic Pain: Herniated Disc, Degenerative Disc Disease, Disc Bulge, Lumbar Spinal Stenosis

2) By Lumbar Spinal Stenosis: Central Stenosis, Lateral Stenosis

3) By Sacroiliac Pain: Sacroiliac Joint Dysfunction, Inflammatory Conditions

4) By Facet-Joint Pain: Facet Joint Syndrome, Osteoarthritis Of The Facet Joints

5) By Radicular Pain: Sciatica, Nerve Root Compression

6) By Muscular Pain: Muscle Strain, Muscle Spasm

7) By Other Types of Pain: Myofascial Pain Syndrome, Spondylolisthesis, Osteoporosis-Related Pain

What Are the Latest Trends in the Chronic Lower Back Pain Market?

In the chronic lower back pain market, the key players are investing in the development of innovative pharmaceuticals to maintain their market standing and better cater to their consumers. The creation of novel drugs noticeably enhances the treatment outcomes for patients suffering from a variety of illnesses. For example, Amneal Pharmaceuticals, an American pharmaceutical entity, unveiled its baclofen oral granule, LYVISPAH (5, 10, and 20 mg) in July 2022. The U.S. Food and Drug Administration (FDA) sanctioned it for the treatment of spasticity associated with multiple sclerosis and other spinal cord disorders. LYVISPAH provides relief from flexor spasms, related pain, clones, and muscular rigidity. The drug ensures customizable dosing with single dose packages of granules in strengths of 5 mg, 10 mg and 20 mg. It is also bioequivalent to oral baclofen tablets. LYVISPAH could provide significant benefits to patients suffering from spinal cord injuries and other related diseases.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/chronic-lower-back-pain-global-market-report

What Are the Key Regional Markets in the Chronic Lower Back Pain Industry?

North America was the largest region in the chronic lower back pain market in 2024. The regions covered in the chronic lower back pain market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9946

This Report Delivers Insight On:

1. How big is the chronic lower back pain market, and how is it changing globally?

2. Who are the major companies in the chronic lower back pain market, and how are they performing?

3. What are the key opportunities and risks in the chronic lower back pain market right now?

4. Which products or customer segments are growing the most in the chronic lower back pain market?

5. What factors are helping or slowing down the growth of the chronic lower back pain market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model